Vaccines for Mycoplasma genitalium
Traditional vaccines can effectively prevent infection of pathogens in most cases. However, due to the relatively complex composition of traditional vaccines and side effects, their application is greatly limited. Therefore, there is an urgent need to develop new vaccines to prevent and control the occurrence and development of diseases.
Mycoplasma genitalium
Mycoplasma genitalium (M. genitalium) first isolated by in 1981 from the urethral specimens of 2 nongonococcal urethritis patients, is the main cause of urinary and reproductive tract infections, which can lead to infertility. Also, M. genitalium is closely associated with pelvic inflammatory disease, respiratory tract infections, and arthritis, etc. M. genitalium isolated from infected animals can be transferred to uninfected animals and cause disease, which may be attached to the genital epithelial cells by surface adhesin proteins and then into the cells, resulting in upregulation of cytokine genes with an associated inflammatory response. M. genitalium has a genome size of only base pairs (bp) and is recognized as an important microbe because it has the smallest genome among any known free-living microorganism. Thus, it has been used as a model for the study of the minimum set of genes necessary to sustain life.
Development of Candidate Vaccines
Vaccine development is the process of identifying unique structures that produce immunoprotection when formulated into vaccines. Using traditional techniques, this process often involves extensive testing and error system testing and elimination of candidate antigens. The traditional method for finding candidates is to immunize the animal with the whole bacterium, use the antiserum to screen the reaction protein, followed by purification of the immunoreactive protein, determine the limited amino acid sequence. This process is quite a time consuming and produces a limited number of candidates within a defined period of time. Creative Biolabs uses genomics and proteomics by application of bioinformatics to expedite the vaccine discovery process and provide vaccine candidates against M. genitalium.
Vaccines for Mycoplasma genitalium
Mycoplasma genitalium adhesion protein (MgPa) is a major adhesion protein located the M. genitalium cell membrane and plays an important role in the formation of tip structures and the attachment of M. genitalium to host cells. In addition, MgPa is also an important neutralizing antigen and its C-terminal domain is strongly immunogenic, especially in the region of 1248 to 1364 aa. This immunogenic domain is very important for the diagnosis and vaccine development of M. genitalium. Studies have shown that mimic epitopes screened by phage display peptide libraries are antigen-specific and can be used as immunogens to stimulate immune responses in the body. Therefore, small molecule epitope vaccines can be developed based on these mimotopes. Although the epitope vaccines contain a shorter amino acid sequence of the antigen epitope, they could efficiently be recognized by the immune system and presented by antigen-presenting cells, inducing humoral and cellular immune responses in the body.
Our Services for Mycoplasma genitalium Vaccines
The Advantages of Our Vaccines
- Highly targeted and unaffected by inhibitory epitopes
- Still effective even if an antigenic variation
- Formation of conformational epitope
- High immunogenicity without modification
Empowered by leading technology and years of experience in the bacterial vaccines, Creative Biolabs is able to provide all services for M. genitalium vaccines for all research and industrial customers. If you need professional, reliable and quality services, please entrust our professional team to provide the best workflow choice for your research goals.
All of our products can only be used for research purposes. These vaccine ingredients CANNOT be used directly on humans or animals.
